OOIR: Observatory of International Research

Papers

(The median citation count of Journal of Pharmacokinetics and Pharmacodynamics is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Translational physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies	36
Population pharmacokinetic and pharmacodynamic model of propofol externally validated in Korean elderly subjects	30
Application of different approaches to generate virtual patient populations for the quantitative systems pharmacology model of erythropoiesis	30
Achieving big with small: quantitative clinical pharmacology tools for drug development in pediatric rare diseases	26
Advancing inclusive healthcare through PBPK modelling: predicting the impact of CYP genotypes and enzyme ontogenies on infant exposures of venlafaxine and its active metabolite O-desmethylvenlafaxine	25
Mixed effect estimation in deep compartment models: Variational methods outperform first-order approximations	22
Learning pharmacometric covariate model structures with symbolic regression networks	22
Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trials	16
Semi-mechanistic modeling of resistance development to β-lactam and β-lactamase-inhibitor combinations	16
Correction: Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson’s disease	16
Translational population target binding model for the anti-FcRn fragment antibody efgartigimod	15
Current practices for QSP model assessment: an IQ consortium survey	15
Convolution-based approach for modeling the paliperidone extended release and Long-Acting Injectable (LAI) PK of once-, and three-monthly products administration and for optimizing the development of	15
ADPO: automatic-differentiation-assisted parametric optimization	14
Model-informed approach to estimate treatment effect in placebo-controlled clinical trials using an artificial intelligence-based propensity weighting methodology to account for non-specific responses	14
Early exposure-response modeling of an interferon-beta monoclonal antibody (dazukibart) in adults with dermatomyositis	14
Population pharmacokinetics and pharmacodynamics of efmarodocokin alfa (IL-22Fc)	13
Training the next generation of pharmacometric modelers: a multisector perspective	12
Comparison of monoclonal antibody disposition predictions using different physiologically based pharmacokinetic modelling platforms	12
Comparison of the power and type 1 error of total score models for drug effect detection in clinical trials	11
Informatics for toxicokinetics	11
Imputation of missing clock times – application to procalcitonin concentration time course after birth	11
Generative models for synthetic data generation: application to pharmacokinetic/pharmacodynamic data	10
Mechanistic inference of the metabolic rates underlying $$^{13}$$C breath test curves	10
Oral docetaxel plus encequidar – A pharmacokinetic model and evaluation against IV docetaxel	10

Population pharmacokinetics of the dual endothelin receptor antagonist aprocitentan in subjects with or without essential or resistant hypertension	9
Expansion of platform physiologically-based pharmacokinetic model for monoclonal antibodies towards different preclinical species: cats, sheep, and dogs	9
Translational pharmacokinetic and pharmacodynamic modelling of the anti-ADAMTS-5 NANOBODY® (M6495) using the neo-epitope ARGS as a biomarker	9
A system pharmacology Boolean network model for the TLR4-mediated inflammatory response in early sepsis	9
Maximum a posteriori Bayesian methods out-perform non-compartmental analysis for busulfan precision dosing	8
A translational physiologically-based pharmacokinetic model for MMAE-based antibody-drug conjugates	8
Risks encountered when not adjusting for diurnal variation and food effect in QTcF analysis based on phase I data	8
Latent variable indirect response modeling of clinical efficacy endpoints with combination therapy: application to guselkumab and golimumab in patients with ulcerative colitis	8
Scoping review of the role of pharmacometrics in model-informed drug development	8
Uncertainty undermines the validity of antimicrobial pharmacodynamics	8
Application of model-informed drug development (MIDD) for dose selection in regulatory submissions for drug approval in Japan	8
Exploring Inductive Linearization for simulation and estimation with an application to the Michaelis–Menten model	7
Longitudinal modeling of efficacy response in patients with lupus nephritis receiving belimumab	7
An automated pipeline to generate initial estimates for population Pharmacokinetic base models	7
Correction to: Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trials	7
Five multivariate Duchenne muscular dystrophy progression models bridging six-minute walk distance and MRI relaxometry of leg muscles	7
Advancing cancer drug development with mechanistic mathematical modeling: bridging the gap between theory and practice	7
Stochastic pharmacodynamics of a heterogeneous tumour-cell population	7
Thanks to our Reviewers of 2022!	7
Leveraging large language models in pharmacometrics: evaluation of NONMEM output interpretation and simulation capabilities	7
PBPK model for antibody disposition in mouse brain: validation using large-pore microdialysis data	7
A quantitative systems pharmacology model of plasma kallikrein-kinin system dysregulation in hereditary angioedema	7
A quantitative modeling framework to understand the physiology of the hypothalamic-pituitary-adrenal axis and interaction with cortisol replacement therapy	6
Population pharmacokinetic/pharmacodynamic modeling of nifekalant injection with varies dosing plan in Chinese volunteers: a randomized, blind, placebo-controlled study	6
A quantitative systems pharmacology model of plasma potassium regulation by the kidney and aldosterone	6
Characterization of CAR-T cellular kinetics and efficacy in solid tumor patients with and without prior lymphodepletion chemotherapy using a PBPK-PD model	6
APOE4 genotypes and the trajectory of biomarkers, neuroimaging, and cognitive measures in Alzheimer’s Disease: A mixed-effects disease progression model	6
The impact of misspecified covariate models on inclusion and omission bias when using fixed effects and full random effects models	6
Sampling from covariate distribution may not always be necessary in PK/PD simulations: illustrative examples with antibiotics	6
ChatGPT and Gemini large language models for pharmacometrics with NONMEM: comment	6
A physiologically-based quantitative systems pharmacology model for mechanistic understanding of the response to alogliptin and its application in patients with renal impairment	5
A QSP PDE model of ADC transport and kinetics in a growing or shrinking tumor	5
Impact of model misspecification on model-based tests in PK studies with parallel design: real case and simulation studies	5
On the existence conditions of interaction indices in response surface models	5
Correction to: Classical structural identifiability methodology applied to low-dimensional dynamic systems in receptor theory	5
Global sensitivity analysis in physiologically-based pharmacokinetic/pharmacodynamic models of inhaled and opioids anesthetics and its application to generate virtual populations	5
Subgroup identification-based model selection to improve the predictive performance of individualized dosing	5
Computing optimal drug dosing with OptiDose: implementation in NONMEM	5
External control arms for rare diseases: building a body of supporting evidence	5
In memory of Dr. Thomas M. Ludden: a pioneer in pharmacometrics, a mentor to many, and a legacy of compassionate science	5
A physics-informed neural network approach for estimating population-level pharmacokinetic parameters from aggregated concentration data	5
JPKPD October Special Issue - Commentary	5
An exploratory analysis of the performance of methylphenidate regimens based on a PKPD model of dopamine and norepinephrine transporter occupancy	5
Special issue: Model-informed drug development in rare diseases: connecting the dots in an information rich ecosystem	5
How drug onset rate and duration of action affect drug forgiveness	5
Identification and characterization of virtual sub-populations through phenotype-guided filtering. The challenging case of nonidentifiable models in the context of therapeutic evaluation	5
Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates	5
A note on phase I interleaved versus parallel group ascending dose designs for concentration-QTc analyses	4
No QT interval prolongation effect of sepiapterin: a concentration-QTc analysis of pooled data from phase 1 and phase 3 studies in healthy volunteers and patients with phenylketonuria	4
A population pharmacokinetics model of balovaptan to support dose selection in adult and pediatric populations	4

Utility of a physiologically-based pharmacokinetic model for investigating time-dependent variability in the fetal-to-maternal plasma concentration ratio of digoxin	4
Impact of covariate model building methods on their clinical relevance evaluation in population pharmacokinetic analyses: comparison of the full model, stepwise covariate model (SCM) and SCM+ approach	4
Do P-glycoprotein-mediated drug-drug interactions at the blood-brain barrier impact morphine brain distribution?	4
Should patients skip late doses of medication? A pharmacokinetic perspective	4
Empirical bayes approach for dynamic bayesian borrowing for clinical trials in rare diseases	4
Correction: Oral docetaxel plus encequidar – a pharmacokinetic model and evaluation against IV docetaxel	4
Note on importance of correct stoichiometric assumptions for modeling of monoclonal antibodies	4
On inductive biases for the robust and interpretable prediction of drug concentrations using deep compartment models	4
Mechanistic incorporation of FcRn binding in plasma and endosomes in a whole body PBPK model for large molecules	4
Exposure-safety Markov modeling of ocular adverse events in patient populations treated with tisotumab vedotin	4
Aggregate data modelling: A fast implementation for fitting pharmacometrics models to summary-level data in R	4
Generation and application of avatars in pharmacometric modelling	4
Comparison of sequential and joint nonlinear mixed effects modeling of tumor kinetics and survival following Durvalumab treatment in patients with metastatic urothelial carcinoma	3
A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development	3
International society of Pharmacometrics Mentorship Program (IMP): feedback survey from the first cohort of mentor-mentee pairs	3
Population pharmacokinetic analyses of pozelimab in patients with CD55-deficient protein-losing enteropathy (CHAPLE disease)	3
Development of a population pharmacokinetics model and an R-Shiny simulation platform for moxifloxacin pharmacokinetics in non-human primates	3
The future of rare disease drug development: the rare disease cures accelerator data analytics platform (RDCA-DAP)	3
Characterization of anti-drug antibody dynamics using a bivariate mixed hidden-markov model by nonlinear-mixed effects approach	3
Correction to: Training the next generation of pharmacometric modelers: a multisector perspective	3
Challenges, approaches and enablers: effectively triangulating towards dose selection in pediatric rare diseases	3
Computing optimal drug dosing regarding efficacy and safety: the enhanced OptiDose method in NONMEM	3
Explaining in-vitro to in-vivo efficacy correlations in oncology pre-clinical development via a semi-mechanistic mathematical model	3
An industry perspective on current QSP trends in drug development	3
A structure-preserving hybrid learning framework for compartmental pharmacokinetic models	3
Advancing drug development with “Fit-for-Purpose” modeling informed approaches	2
Leveraging large language models to compare perspectives on integrating QSP and AI/ML	2
Dos and don’ts for concentration - QTc analysis as primary analysis for assay sensitivity assessment	2
A next generation mathematical model for the in vitro to clinical translation of T-cell engagers	2
Interoccasion variability in population pharmacokinetic models: identifiability, influence, interdependencies and derived study design recommendations	2
Time Scale Calculus: a new approach to multi-dose pharmacokinetic modeling	2
Changes in Associate Editors at the Journal of Pharmacokinetics and Pharmacodynamics	2
A proof of concept reinforcement learning based tool for non parametric population pharmacokinetics workflow optimization	2
Computational neurosciences and quantitative systems pharmacology: a powerful combination for supporting drug development in neurodegenerative diseases	2
Virtual clinical trials via a QSP immuno-oncology model to simulate the response to a conditionally activated PD-L1 targeting antibody in NSCLC	2
Predicting tumor dynamics in treated patients from patient-derived-xenograft mouse models: a translational model-based approach	2
Concentration response analyses for QT data with several active compounds	2
Physiologically-based pharmacokinetic model for predicting drug-drug interactions perpetrated by posaconazole in healthy subjects with normal weight and obesity: Concomitant use and washout	2
Towards a platform quantitative systems pharmacology (QSP) model for preclinical to clinical translation of antibody drug conjugates (ADCs)	2
Towards a comprehensive assessment of QSP models: what would it take?	2
A review of the physiological effects of microgravity and innovative formulation for space travelers	2
Development of minimal physiologically-based pharmacokinetic-pharmacodynamic models for characterizing cellular kinetics of CAR T cells following local deliveries in mice	2
A hybrid PKPD agent-based model of the tumour immune interaction: effects of anti-cancer combination therapy	2
Fourteenth American Conference on Pharmacometrics (ACoP14) – Innovation and Diversity: Redefining Pharmacometrics	2
Translational two-pore PBPK model to characterize whole-body disposition of different-size endogenous and exogenous proteins	2
Rare oncology therapeutics: review of clinical pharmacology package of drug approvals (2019–2023) by US FDA, best practices and recommendations	2
A quantitative systems pharmacology model for simulating OFF-Time in augmentation trials for Parkinson’s disease: application to preladenant	2
Correction: External control arms for rare diseases: building a body of supporting evidence	2
A minimal physiologically based pharmacokinetic model to study the combined effect of antibody size, charge, and binding affinity to FcRn/antigen on antibody pharmacokinetics	2
Pharmacometrics education for all by overcoming language barriers to enhance global collaboration	2
Impact of covariate model building methods on their clinical relevance evaluation in population pharmacokinetic analyses: comparison of the full model, stepwise covariate model (SCM) and SCM+ approac	2
Tracer kinetic modeling of a 14 kDa anti-CD8 PET tracer (2C8v144) for in vivo estimation of CD8 expression in tissue and blood, binding affinity, and total body receptor occupancy	2